Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Liver Neoplasms 2Carcinoma, Hepatocellular 2Pituitary Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Nelson Syndrome 1Lymphoma, Follicular 1Hypoglycemia 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

Oxaliplatin 30Gemcitabine 28Fluorouracil 27Capecitabine 22Leucovorin 19pembrolizumab 15130-nm albumin-bound paclitaxel 13Irinotecan 12Cisplatin 11Bevacizumab 11Albumin-Bound Paclitaxel 11Paclitaxel 10Ramucirumab 8Radiotherapy 8Docetaxel 8Nivolumab 7trastuzumab deruxtecan 6Cyclophosphamide 6Taxes 5Drug Therapy 5durvalumab 4Trastuzumab 4Metformin 4zolbetuximab 3spartalizumab 3folfirinox 3cemiplimab 3XELOX 3Surgical Procedures, Operative 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × pasireotide × Gastrointestinal × Clear all
NCT01385956 2020-09-28

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
20 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡